pmid	doi	year	title	Hugo_Symbol
33634586	10.1002/cyto.b.21995	2022	Flow cytometry detection of CD138 expression continuum between monotypic B and plasma cells is associated with both high IgM peak levels and MYD88 mutation and contributes to diagnosis of Waldenström macroglobulinemia.	MYD88
33682304	10.1002/cyto.b.22000	2022	VS38 staining contributes to a novel gating strategy in flow cytometry for small B cell lymphoma, especially in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.	MYD88
34325497	10.4143/crt.2021.752	2022	Plasma Circulating Tumor DNA in Patients with Primary Central Nervous System Lymphoma.	MYD88
34411492	10.1139/cjpp-2021-0007	2022	Colchicine attenuates renal ischemia-reperfusion-induced liver damage: implication of TLR4/NF-κB, TGF-β, and <i>BAX</i> and <i>Bcl-2</i> gene expression.	MYD88
34448823	10.1182/bloodadvances.2021004212	2022	The molecular hallmarks of primary and secondary vitreoretinal lymphoma.	MYD88
34638136	10.1182/bloodadvances.2020003698	2022	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.	MYD88
34654055	10.1182/bloodadvances.2021006034	2022	Diffuse large B-cell lymphomas in adults with aberrant coexpression of CD10, BCL6, and MUM1 are enriched in IRF4 rearrangements.	MYD88
34674984	10.1016/j.clml.2021.09.014	2022	Bing-Neel Syndrome: Update on the Diagnosis and Treatment.	MYD88
34793256	10.1200/JCO.21.01194	2022	Venetoclax in Previously Treated Waldenström Macroglobulinemia.	MYD88
34802044	10.1038/s41379-021-00954-z	2022	A novel diagnostic approach for the classification of small B-cell lymphoid neoplasms based on the NanoString platform.	MYD88
34895930	10.1016/j.pathol.2021.09.018	2022	Cutaneous lymphoplasmacytic lymphoma with MYD88 L265P mutation, bone marrow involvement, and paraproteinaemia.	MYD88
34961399	10.1080/10428194.2021.2018584	2022	Discriminating between Waldenström macroglobulinemia and marginal zone lymphoma using logistic LASSO regression.	MYD88
34980578	10.1016/j.clml.2021.11.014	2022	SOHO State of the Art Updates and Next Questions: Waldenström Macroglobulinemia - 2021 Update on Management and Future Directions.	MYD88
34997652	10.1111/ejh.13736	2022	Mutation profiling of circulating tumor DNA identifies distinct mutation patterns in non-Hodgkin lymphoma.	MYD88
35020191	10.1111/bjh.18036	2022	Diagnosis and management of Waldenström macroglobulinaemia-A British Society for Haematology guideline.	MYD88
35028710	10.1007/s00428-021-03265-5	2022	Cell-of-origin classification using the Hans and Lymph2Cx algorithms in primary cutaneous large B-cell lymphomas.	MYD88
35030632	10.1182/bloodadvances.2021006410	2022	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients.	MYD88
35044826	10.1126/sciadv.abl4644	2022	Preneoplastic somatic mutations including <i>MYD88</i><sup>L265P</sup> in lymphoplasmacytic lymphoma.	MYD88
35073397	10.1039/d1lc01055g	2022	Direct MYD88<sup>L265P</sup> gene detection for diffuse large B-cell lymphoma (DLBCL) <i>via</i> a miniaturised CRISPR/dCas9-based sensing chip.	MYD88
35096069	10.1155/2022/1182384	2022	Utility of Bruton's Tyrosine Kinase Inhibitors in Light Chain Amyloidosis Caused by Lymphoplasmacytic Lymphoma (Waldenström's Macroglobulinemia).	MYD88
35106936	10.1002/cam4.4550	2022	SGK1 mutation status can further stratify patients with germinal center B-cell-like diffuse large B-cell lymphoma into different prognostic subgroups.	MYD88
35126963	10.1177/20406207211072839	2022	MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical characteristics, and targeted therapy.	MYD88
35142151	10.3324/haematol.2021.279908	2022	A pilot study of the use of dynamic analysis of cell-free DNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas.	MYD88
35149375	10.1016/j.ctarc.2022.100527	2022	Current approach to Waldenström Macroglobulinemia.	MYD88
35154721	10.1002/ccr3.5372	2022	Successful treatment with bortezomib for refractory fever associated with myelodysplastic syndrome with underlying lymphoplasmacytic lymphoma.	MYD88
35156897	10.1080/21655979.2022.2032939	2022	MicroRNA-885-3p alleviates bronchial epithelial cell injury induced by lipopolysaccharide via toll-like receptor 4.	MYD88
35158867	10.3390/cancers14030598	2022	Diagnosing Vitreoretinal Lymphomas-An Analysis of the Sensitivity of Existing Tools.	MYD88
35169086	10.11477/mf.1436204531	2022	[Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma].	MYD88
35200564	10.3390/curroncol29020065	2022	Comprehensive Laboratory Diagnostic Workup for Patients with Suspected Intraocular Lymphoma including Flow Cytometry, Molecular Genetics and Cytopathology.	MYD88
35210172	10.1016/j.preteyeres.2022.101053	2022	Challenges in the diagnosis and management of vitreoretinal lymphoma - Clinical and basic approaches.	MYD88
35223507	10.3389/fonc.2022.824632	2022	<i>PIM1</i> and <i>CD79B</i> Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS.	MYD88
35236331	10.1186/s12885-022-09237-5	2022	Prognostic mutational subtyping in de novo diffuse large B-cell lymphoma.	MYD88
35255429	10.1016/j.anndiagpath.2021.151886	2022	De Novo CD5-positive diffuse large B-cell lymphoma: A genomic profiling study and prognostic analysis of 46 patients.	MYD88
35255496	10.1182/bloodadvances.2021006147	2022	A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas.	MYD88
35265542	10.12890/2022_003106	2022	Lymphoplasmacytic Lymphoma with Only Lambda Light Chain Monoclonal Paraprotein Expression.	MYD88
35267569	10.3390/cancers14051264	2022	The Biology of Ocular Adnexal Marginal Zone Lymphomas.	MYD88
35281910	10.3389/fphar.2022.857869	2022	Engineered Bacteria EcN-MT Alleviate Liver Injury in Cadmium-Exposed Mice <i>via</i> its Probiotics Characteristics and Expressing of Metallothionein.	MYD88
35300216	10.2147/JIR.S341355	2022	The Mutation of <i>BTG2</i> Gene Predicts a Poor Outcome in Primary Testicular Diffuse Large B-Cell Lymphoma.	MYD88
35339405	10.1016/j.clml.2022.02.005	2022	SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenström Macroglobulinemia.	MYD88
35339566	10.1016/j.humpath.2022.03.008	2022	Myeloid nuclear differentiation antigen: an aid in differentiating lymphoplasmacytic lymphoma and splenic marginal zone lymphoma in bone marrow biopsies at presentation.	MYD88
35340094	10.1111/vco.12816	2022	Anticancer activity of IRAK-4 inhibitors against canine lymphoid malignancies.	MYD88
35358350	10.1002/ajh.26552	2022	First- versus second-generation Bruton tyrosine kinase inhibitors in Waldenström's Macroglobulinemia: A systematic review and meta-analysis.	MYD88
35359040	10.3760/cma.j.cn112151-20211220-00915	2022	[Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma].	MYD88
35370644	10.3389/fphar.2022.842723	2022	Baicalein Ameliorates Myocardial Ischemia Through Reduction of Oxidative Stress, Inflammation and Apoptosis via TLR4/MyD88/MAPK<sub>S</sub>/NF-κB Pathway and Regulation of Ca<sup>2+</sup> Homeostasis by L-type Ca<sup>2+</sup> Channels.	MYD88
35401516	10.3389/fimmu.2022.842439	2022	Oncogenic Mutations and Tumor Microenvironment Alterations of Older Patients With Diffuse Large B-Cell Lymphoma.	MYD88
35454017	10.3390/diagnostics12040969	2022	Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.	MYD88
35506035	10.5114/wo.2022.115675	2022	Prognostic values of myeloid differentiation factor 88 (MYD88) and transducin (β)-like receptor 1 (TBLR1) expression in tissues of diffuse large B-cell non-Hodgkin lymphoma patients - an immunohistochemical study.	MYD88
35510210	10.1177/20406207221093962	2022	Treatment paradigm in Waldenström macroglobulinemia: frontline therapy and beyond.	MYD88
35514998	10.3389/fimmu.2022.894464	2022	Case Report: Therapeutic Use of Ibrutinib in a Patient With Schnitzler Syndrome.	MYD88
35537114	10.1182/bloodadvances.2022007279	2022	Landscape of immunoglobulin heavy chain gene repertoire and its clinical relevance to LPL/WM.	MYD88
35538064	10.1038/s41467-022-30050-y	2022	The genomic and transcriptional landscape of primary central nervous system lymphoma.	MYD88
35554927	10.1002/eji.202149746	2022	Spatial transcriptome of a germinal center plasmablastic burst hints at MYD88/CD79B mutants-enriched diffuse large B-cell lymphomas.	MYD88
35628381	10.3390/ijms23105570	2022	<i>MYD88</i> Mutations: Transforming the Landscape of IgM Monoclonal Gammopathies.	MYD88
35646048	10.3389/fgene.2022.878618	2022	Whole-Genome/Exome Sequencing Uncovers Mutations and Copy Number Variations in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	MYD88
35680596	10.3760/cma.j.issn.0253-2727.2022.05.007	2022	[Exploring the detection of MYD88 mutation in patients with Waldenström macroglobulinemia by different methods and specimens].	MYD88
35759728	10.1182/blood.2022015926	2022	Aberrant expansion of spontaneous splenic germinal centers induced by hallmark genetic lesions of aggressive lymphoma.	MYD88
35761836	10.1155/2022/3864863	2022	Mesenchymal Stem Cell Exosomal miR-146a Mediates the Regulation of the TLR4/MyD88/NF-<i>κ</i>B Signaling Pathway in Inflammation due to Diabetic Retinopathy.	MYD88
35794278	10.1007/s00277-022-04910-y	2022	First Latin America report on the diagnostic utility of the study of the MYD88 L265P gene mutation in patients with Waldenström Macroglobulinemia.	MYD88
35813102	10.1097/HS9.0000000000000746	2022	Dutch Physician's Perspectives on Diagnosis and Treatment of Waldenström's Macroglobulinemia Before and After the Implementation of a National Guideline.	MYD88
35877223	10.3390/curroncol29070363	2022	Concurrent Waldenstrom's Macroglobulinemia and Myelodysplastic Syndrome with a Sequent t(10;13)(p13;q22) Translocation.	MYD88
35879731	10.1186/s40364-022-00401-4	2022	Dynamic change of soluble interleukin-2 receptor distinguished molecular heterogeneity and microenvironment alterations in diffuse large B-cell lymphoma.	MYD88
35903524	10.1016/j.jsps.2022.05.009	2022	Genistein promotes M1 macrophage apoptosis and reduces inflammatory response by disrupting miR-21/TIPE2 pathway.	MYD88
35911113	10.3389/fnut.2022.907386	2022	Selenium Nanoparticles Improved Intestinal Health Through Modulation of the NLRP3 Signaling Pathway.	MYD88
35928872	10.3389/fonc.2022.932674	2022	Cell-Free DNA Sequencing of Intraocular Fluid as Liquid Biopsy in the Diagnosis of Vitreoretinal Lymphoma.	MYD88
35932039	10.1186/s13000-022-01244-1	2022	Mu heavy chain disease with MYD88 L265P mutation: an unusual manifestation of lymphoplasmacytic lymphoma.	MYD88
35937947	10.1155/2022/6441139	2022	Genomic Mutation Landscape of Primary Breast Lymphoma: Next-Generation Sequencing Analysis.	MYD88
35939775	10.1200/GO.21.00380	2022	Treatment and Survival Outcomes of Waldenstrom Macroglobulinemia in Latin American Patients: A Multinational Retrospective Cohort Study.	MYD88
35949601	10.3892/ol.2022.13418	2022	Hemophagocytic lymphohistiocytosis as an onset of diffuse large B-cell lymphoma: A case report.	MYD88
35952646	10.1016/j.chom.2022.07.003	2022	Butyrate-producing Eubacterium rectale suppresses lymphomagenesis by alleviating the TNF-induced TLR4/MyD88/NF-κB axis.	MYD88
35952929	10.1016/j.oret.2022.08.005	2022	Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A potential less-invasive method for diagnosis and treatment response assessment.	MYD88
35968590	10.3760/cma.j.issn.0253-2727.2022.06.006	2022	[Large B-cell lymphoma with IRF4 rearrangement: six case reports and a literature review].	MYD88
35973369	10.1016/j.intimp.2022.109138	2022	Zanubrutinib ameliorates lipopolysaccharide-induced acute lung injury via regulating macrophage polarization.	MYD88
36003901	10.2147/BLCTT.S259860	2022	Differential Diagnosis of Waldenström's Macroglobulinemia and Early Management: Perspectives from Clinical Practice.	MYD88
36006771	10.1097/PAS.0000000000001957	2022	Clinicopathologic Features and Genomic Signature of De Novo CD5+ Diffuse Large B-Cell Lymphoma: A Multicenter Collaborative Study.	MYD88
36051079	10.1002/jha2.428	2022	Targetable alterations in primary extranodal diffuse large B-cell lymphoma.	MYD88
36053490	10.1002/hon.3073	2022	Clinical significance of MYD88 non-L265P mutations in diffuse large B-cell lymphoma.	MYD88
36055572	10.1016/j.clim.2022.109105	2022	A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.	MYD88
36059608	10.3389/fonc.2022.955080	2022	Circulating cell-free DNA and IL-10 from cerebrospinal fluids aid primary vitreoretinal lymphoma diagnosis.	MYD88
36081566	10.3389/fonc.2022.941347	2022	Molecular subtyping of CD5+ diffuse large B-cell lymphoma based on DNA-targeted sequencing and Lymph2Cx.	MYD88
31418635	10.1080/09273948.2019.1636093	2021	PreservCyt Is an Optimal Fixative that Permits Cytologic and Molecular Analyses of Vitreoretinal Lymphoma Biopsies.	MYD88
31603365	10.1080/09273948.2019.1657903	2021	Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.	MYD88
32139889	10.1038/s41375-020-0766-4	2021	Targeting of inflammatory pathways with R2CHOP in high-risk DLBCL.	MYD88
32447345	10.1038/s41375-020-0874-1	2021	Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response.	MYD88
32583848	10.1093/neuonc/noaa145	2021	Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.	MYD88
32591642	10.1038/s41375-020-0934-6	2021	Identification of the SRC-family tyrosine kinase HCK as a therapeutic target in mantle cell lymphoma.	MYD88
32810857	10.1159/000509286	2021	Current and Emerging Treatments for Waldenström Macroglobulinemia.	MYD88
32845738	10.1080/09273948.2020.1787460	2021	Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.	MYD88
32965155	10.1080/09273948.2020.1802488	2021	Serial Detection of <i>MYD88</i> L265P Mutation in the Aqueous Humor of a Patient with Vitreoretinal Lymphoma for Disease Monitoring.	MYD88
32970964	10.1165/rcmb.2020-0083OC	2021	<i>Aspergillus</i> <i>fumigatus</i> Recognition by Dendritic Cells Negatively Regulates Allergic Lung Inflammation through a TLR2/MyD88 Pathway.	MYD88
32973328	10.1038/s41379-020-00685-7	2021	The clinicopathological and molecular features of sinusoidal large B-cell lymphoma.	MYD88
33025009	10.1182/blood.2020004918	2021	MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis.	MYD88
33079297	10.1007/s10014-020-00386-8	2021	Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.	MYD88
33202420	10.1182/blood.2020008520	2021	EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.	MYD88
33217360	10.1016/j.hemonc.2020.10.003	2021	Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.	MYD88
33221324	10.1016/j.ophtha.2020.11.018	2021	Single B-Cell Genomic Analyses Differentiate Vitreoretinal Lymphoma from Chronic Inflammation.	MYD88
33222046	10.1007/s12185-020-03038-x	2021	Monitoring of MYD88 L265P mutation by droplet digital polymerase chain reaction for prediction of early relapse in a patient with Bing-Neel syndrome.	MYD88
33232972	10.1182/blood.2020005244	2021	Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.	MYD88
33263441	10.1080/17474086.2021.1856652	2021	Development of molecular intervention strategies for B-cell lymphoma.	MYD88
33311649	10.1038/s41379-020-00720-7	2021	Targeted massively parallel sequencing of mature lymphoid neoplasms: assessment of empirical application and diagnostic utility in routine clinical practice.	MYD88
33368476	10.1002/ajh.26082	2021	Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management.	MYD88
33395752	10.1016/j.tranon.2020.100977	2021	Biomarkers of response to ibrutinib plus nivolumab in relapsed diffuse large B-cell lymphoma, follicular lymphoma, or Richter's transformation.	MYD88
33447829	10.1158/2643-3230.BCD-19-0059	2021	An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities.	MYD88
33455071	10.1111/ijlh.13467	2021	The relative expression levels of CD148 and CD180 on clonal B cells and CD148/CD180 median fluorescence intensity ratios are useful in the characterization of mature B cell lymphoid neoplasms infiltrating blood and bone marrow - Results from a single centre pilot study.	MYD88
33488968	10.1021/acsmedchemlett.0c00474	2021	Design, Synthesis, and Biological Evaluation of IRAK4-Targeting PROTACs.	MYD88
33512416	10.1182/blood.2020007245	2021	Frequent genetic alterations in immune checkpoint-related genes in intravascular large B-cell lymphoma.	MYD88
33569985	10.1080/10428194.2021.1881514	2021	Clinical application of genomics in Waldenström macroglobulinemia.	MYD88
33581493	10.1016/j.ctarc.2021.100310	2021	Diversity of genetic alterations of primary central nervous system lymphoma in Hispanic versus non-Hispanic patients.	MYD88
33620087	10.1111/bjh.17357	2021	MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.	MYD88
33622752	10.1136/bcr-2020-240242	2021	IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.	MYD88
33643507	10.14740/jh767	2021	Histologic Transformation in an Untreated Waldenstrom's Macroglobulinemia After 14 Years: Case Report and Review of the Literature.	MYD88
33677885	10.3760/cma.j.cn112151-20200513-00383	2021	[Clinicopathological features and MYD88 L265P mutation status of intravascular large B cell lymphoma].	MYD88
33685720	10.1016/j.pathol.2021.01.002	2021	New developments in non-Hodgkin lymphoid malignancies.	MYD88
33724154	10.1080/21505594.2021.1899674	2021	Pathogenicity and virulence of Japanese encephalitis virus: Neuroinflammation and neuronal cell damage.	MYD88
33735664	10.1016/j.neo.2021.02.002	2021	Molecular and genetic biomarkers implemented from next-generation sequencing provide treatment insights in clinical practice for Waldenström macroglobulinemia.	MYD88
33735913	10.1182/blood.2020010137	2021	A rapid genotyping panel for detection of primary central nervous system lymphoma.	MYD88
33747936	10.3389/fonc.2021.622648	2021	Genomic Mutation Profile of Primary Gastrointestinal Diffuse Large B-Cell Lymphoma.	MYD88
33777778	10.3389/fonc.2021.628807	2021	Mutational Profile and Clonal Evolution of Relapsed/Refractory Diffuse Large B-Cell Lymphoma.	MYD88
33899787	10.1097/PAS.0000000000001691	2021	The Positivity of Phosphorylated STAT3 Is a Novel Marker for Favorable Prognosis in Germinal Center B-Cell Type of Diffuse Large B-Cell Lymphoma.	MYD88
33907976	10.1007/s12185-021-03157-z	2021	Transformation to diffuse large B-cell lymphoma with germinal center B-cell like subtype and discordant light chain expression in a patient with Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.	MYD88
33909933	10.1002/ajh.26210	2021	Assessment of fixed-duration therapies for treatment-naïve Waldenström macroglobulinemia.	MYD88
33962927	10.1136/bcr-2021-241707	2021	Chylothorax as a complication of Waldenström macroglobulinaemia with a patient's perspective.	MYD88
33979991	10.3324/haematol.2020.278258	2021	Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with <i>MYD88</i> L265P mutation.	MYD88
34009095	10.1080/09273948.2021.1878233	2021	Consensus Recommendations for the Diagnosis of Vitreoretinal Lymphoma.	MYD88
34017329	10.3389/fimmu.2021.641692	2021	Continuous MYD88 Activation Is Associated With Expansion and Then Transformation of IgM Differentiating Plasma Cells.	MYD88
34038803	10.1016/j.carpath.2021.107348	2021	Endomyocardial biopsy with co-localization of a lymphoplasmacytic lymphoma and AL amyloidosis.	MYD88
34071407	10.3390/cancers13112665	2021	Liquid Biopsy and Other Non-Invasive Diagnostic Measures in PCNSL.	MYD88
34078045	10.3760/cma.j.cn112151-20201201-00882	2021	[Nodal lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia: a clinicopathological and prognostical study].	MYD88
34105469	10.19746/j.cnki.issn.1009-2137.2021.03.017	2021	[Relationship between Polymorphism of miR-155 and Its Target Gene MyD88 and Clinicopathological Features of Diffuse Large B-cell Lymphoma].	MYD88
34113355	10.3389/fimmu.2021.684424	2021	Hippo Pathway Counter-Regulates Innate Immunity in Hepatitis B Virus Infection.	MYD88
34132782	10.1182/blood.2021011405	2021	The HCK/BTK inhibitor KIN-8194 is active in MYD88-driven lymphomas and overcomes mutated BTKCys481 ibrutinib resistance.	MYD88
34163463	10.3389/fimmu.2021.616451	2021	Absence of Non-Canonical, Inhibitory <i>MYD88</i> Splice Variants in B Cell Lymphomas Correlates With Sustained NF-κB Signaling.	MYD88
34173362	10.1097/IAE.0000000000003241	2021	CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.	MYD88
34201186	10.3390/medicina57060592	2021	Frostbite and Cold Agglutinin Disease: Coexistence of Two Entities Leading to Poor Clinical Outcomes.	MYD88
34204385	10.3390/cancers13123032	2021	Cell-Free Total Nucleic Acid-Based Genotyping of Aggressive Lymphoma: Comprehensive Analysis of Gene Fusions and Nucleotide Variants by Next-Generation Sequencing.	MYD88
34236648	10.1007/978-1-0716-1669-7_20	2021	Generation and Surgical Analysis of Genetic Mouse Models to Study NF-κB-Driven Pathogenesis of Diffuse Large B Cell Lymphoma.	MYD88
34254378	10.1111/neup.12739	2021	Primary central nervous system lymphomas with massive intratumoral hemorrhage: Clinical, radiological, pathological, and molecular features of six cases.	MYD88
34255584	10.1080/09273948.2021.1916040	2021	A Case of Spontaneous Regression and Recurrence of Primary Vitreoretinal Lymphoma.	MYD88
34277756	10.3389/fvets.2021.683863	2021	<i>Clostridium butyricum</i> Helps to Alleviate Inflammation in Weaned Piglets Challenged With Enterotoxigenic <i>Escherichia coli</i> K88.	MYD88
34279092	10.1021/acs.jmedchem.1c00103	2021	Discovery of Highly Potent and Selective IRAK1 Degraders to Probe Scaffolding Functions of IRAK1 in ABC DLBCL.	MYD88
34327781	10.1111/cas.15091	2021	Current progress and future perspectives of research on intravascular large B-cell lymphoma.	MYD88
34330762	10.1136/jitc-2021-002410	2021	High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies.	MYD88
34340248	10.1111/bjh.17691	2021	Disease outcomes and biomarkers of progression in smouldering Waldenström macroglobulinaemia.	MYD88
34362495	10.19746/j.cnki.issn.1009-2137.2021.04.020	2021	[The Types and Laboratory Characteristics of Non-Hodgkin Lymphoma with Bone Marrow Invasion as the First Manifestation].	MYD88
34377990	10.1093/noajnl/vdab090	2021	MYD88 L265P mutation in primary central nervous system lymphoma is associated with better survival: A single-center experience.	MYD88
34378195	10.1111/bjh.17765	2021	Genetic subtype classification using a simplified algorithm and mutational characteristics of diffuse large B-cell lymphoma in a Japanese cohort.	MYD88
34405609	10.3760/cma.j.cn112151-20210110-00023	2021	[Characteristics of PD-L1 expression in tumor cells and tumor microenvironment of DLBCL with MYD88 L265P mutation].	MYD88
34439078	10.3390/cancers13163921	2021	Vitreoretinal Lymphoma.	MYD88
34497201	10.11406/rinketsu.62.1139	2021	[Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].	MYD88
34523186	10.1111/cas.15133	2021	Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.	MYD88
34570179	10.1182/bloodadvances.2021004668	2021	Mutational patterns and their correlation to CHIP-related mutations and age in hematological malignancies.	MYD88
34576156	10.3390/ijms22189992	2021	Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy.	MYD88
34589395	10.1016/j.apsb.2020.12.020	2021	Clinical efficacies, underlying mechanisms and molecular targets of Chinese medicines for diabetic nephropathy treatment and management.	MYD88
34606736	10.1080/14728222.2021.1988927	2021	Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma.	MYD88
34651869	10.1002/hon.2933	2021	The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma.	MYD88
34657049		2021	[Circulating Tumor DNA Analysis in Lymphomas].	MYD88
34706861	10.1136/bjophthalmol-2021-319580	2021	Prevalence and prognostic value of <i>MYD88</i> and <i>CD79B</i> mutations in ocular adnexal large B-cell lymphoma: a reclassification of ocular adnexal large B-cell lymphoma.	MYD88
34732622	10.11406/rinketsu.62.1493	2021	[IgG-variant Bing-Neel syndrome diagnosed by detecting MYD88 L265P mutation in the cerebrospinal fluid cells].	MYD88
34739844	10.1016/j.ccell.2021.10.006	2021	Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL.	MYD88
34849377	10.14309/crj.0000000000000689	2021	A Rare Case of Waldenstrom Macroglobulinemia of the Rectosigmoid Colon.	MYD88
34865422	10.3760/cma.j.cn112151-20210316-00208	2021	[Lymphoplasmacytic lymphoma: a clinicopathological and prognostic analysis of 27 cases].	MYD88
34925435	10.3389/fgene.2021.677650	2021	Genetic Landscape of Relapsed and Refractory Diffuse Large B-Cell Lymphoma: A Systemic Review and Association Analysis With Next-Generation Sequencing.	MYD88
34940069	10.3390/curroncol28060430	2021	CD5-Negative, CD10-Negative Low-Grade B-Cell Lymphoproliferative Disorders of the Spleen.	MYD88
34944954	10.3390/cancers13246334	2021	Impact of a Faulty Germinal Center Reaction on the Pathogenesis of Primary Diffuse Large B Cell Lymphoma of the Central Nervous System.	MYD88
34945004	10.3390/cancers13246384	2021	Artificial Neural Networks Predicted the Overall Survival and Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Pancancer Immune-Oncology Panel.	MYD88
35087759	10.3389/fonc.2021.801124	2021	Determinants of Drug Resistance in B-Cell Non-Hodgkin Lymphomas: The Case of Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia.	MYD88
35116576	10.21037/tcr-20-2525	2021	Identification of key mutations in central nervous diffuse large B-cell lymphoma (DLBCL) by comprehensive analysis between sequencing and TCGA database.	MYD88
29629945	10.1097/PAI.0000000000000655	2020	Clonal Evolution in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System.	MYD88
30335535	10.1080/09273948.2018.1533984	2020	Immunohistochemical and Immunocytochemical Analyses in Patients with Vitreoretinal Lymphoma.	MYD88
31123031	10.3324/haematol.2018.214122	2020	<i>MYD88</i> mutations identify a molecular subgroup of diffuse large B-cell lymphoma with an unfavorable prognosis.	MYD88
31286804	10.1080/15548627.2019.1635384	2020	New insights into the interplay between autophagy, gut microbiota and inflammatory responses in IBD.	MYD88
31588566	10.1111/bjh.16210	2020	IgM paraprotein-associated peripheral neuropathy: small CD20-positive B-cell clones may predict a monoclonal gammopathy of neurological significance and rituximab responsiveness.	MYD88
31609782	10.1097/PAS.0000000000001386	2020	Morphologic Patterns and the Correlation With MYD88 L265P, CD79B Mutations in Primary Adrenal Diffuse Large B-Cell Lymphoma.	MYD88
31630277	10.1007/s10014-019-00354-x	2020	Ventricle-predominant primary CNS lymphomas: clinical, radiological and pathological evaluation of five cases and review of the literature.	MYD88
31738823	10.1182/blood.2019002699	2020	Distinct molecular profile of IRF4-rearranged large B-cell lymphoma.	MYD88
31767130	10.1016/j.pathol.2019.09.009	2020	Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis.	MYD88
31776466	10.1038/s41375-019-0661-z	2020	CRL3-SPOP ubiquitin ligase complex suppresses the growth of diffuse large B-cell lymphoma by negatively regulating the MyD88/NF-κB signaling.	MYD88
31814157	10.1002/ajh.25697	2020	Impact of MYD88<sup>L265P</sup> mutation status on histological transformation of Waldenström Macroglobulinemia.	MYD88
31863183	10.1007/s00428-019-02698-3	2020	Lymphomas arising in immune-privileged sites: insights into biology, diagnosis, and pathogenesis.	MYD88
31866281	10.1016/S2352-3026(19)30210-8	2020	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study.	MYD88
31886867	10.1093/jnen/nlz125	2020	Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma.	MYD88
31902622	10.1016/j.pathol.2019.11.002	2020	A practical guide to laboratory investigations at diagnosis and follow up in Waldenström macroglobulinaemia: recommendations from the Medical and Scientific Advisory Group, Myeloma Australia, the Pathology Sub-committee of the Lymphoma and Related Diseases Registry and the Australasian Association of Clinical Biochemists Monoclonal Gammopathy Working Group.	MYD88
31935288	10.1182/bloodadvances.2019000947	2020	Expression of the prosurvival kinase HCK requires PAX5 and mutated MYD88 signaling in MYD88-driven B-cell lymphomas.	MYD88
31960730	10.1080/10428194.2020.1711901	2020	Waldenstrom's macroglobulinemia in the era of immunotherapy.	MYD88
31964218	10.1177/1078155219895079	2020	Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.	MYD88
31992103	10.1080/10428194.2020.1719100	2020	A matched case-control study comparing features, treatment and outcomes between patients with non-IgM lymphoplasmacytic lymphoma and Waldenström macroglobulinemia.	MYD88
32005797	10.1038/s41408-020-0277-6	2020	SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.	MYD88
32006301	10.1007/s11899-020-00559-4	2020	Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia.	MYD88
32012328	10.1002/hon.2718	2020	High throughput sequencing reveals high specificity of TNFAIP3 mutations in ocular adnexal marginal zone B-cell lymphomas.	MYD88
32014679	10.1016/j.ejmech.2020.112092	2020	Design and synthesis of Imidazo[1,2-b]pyridazine IRAK4 inhibitors for the treatment of mutant MYD88 L265P diffuse large B-cell lymphoma.	MYD88
32016162	10.1016/j.ajoc.2020.100597	2020	Lymphoplasmacytic lymphoma infiltrating both lacrimal glands in a patient with Waldenström's macroglobulinemia.	MYD88
32056332	10.1111/cas.14347	2020	Gene expression profiling of primary vitreoretinal lymphoma.	MYD88
32083995	10.1200/JCO.19.02314	2020	Genomic Landscape of Waldenström Macroglobulinemia and Its Impact on Treatment Strategies.	MYD88
32103491	10.1111/bjh.16463	2020	Genomic evolution of ibrutinib-resistant clones in Waldenström macroglobulinaemia.	MYD88
32127472	10.1073/pnas.1921187117	2020	Regulation of B cell receptor-dependent NF-κB signaling by the tumor suppressor KLHL14.	MYD88
32161170	10.1128/JVI.02123-19	2020	Interleukin-1 Receptor-Associated Kinase (IRAK) Signaling in Kaposi Sarcoma-Associated Herpesvirus-Induced Primary Effusion Lymphoma.	MYD88
32170099	10.1038/s41408-020-0305-6	2020	Nfkbie-deficiency leads to increased susceptibility to develop B-cell lymphoproliferative disorders in aged mice.	MYD88
32173361	10.1016/j.exphem.2020.03.001	2020	Molecular characterization of sorted malignant B cells from patients clinically identified with mantle cell lymphoma.	MYD88
32187361	10.1182/blood.2019003535	2020	Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.	MYD88
32201861	10.1093/noajnl/vdaa018	2020	Primary CNS lymphoma commonly expresses immune response biomarkers.	MYD88
32239385	10.1007/s11523-020-00710-4	2020	Genomic Alterations and MYD88<sup>MUT</sup> Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib.	MYD88
32249238	10.3960/jslrt.19041	2020	Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma.	MYD88
32267931	10.1182/bloodadvances.2019000980	2020	Primary vitreoretinal lymphomas display a remarkably restricted immunoglobulin gene repertoire.	MYD88
32272395	10.1016/j.intimp.2020.106445	2020	4-hydroxybenzo[d]oxazol-2(3H)-one ameliorates LPS/D-GalN-induced acute liver injury by inhibiting TLR4/NF-κB and MAPK signaling pathways in mice.	MYD88
32322395	10.1186/s40364-020-00189-1	2020	TBL1XR1 mutation predicts poor outcome in primary testicular diffuse large B-cell lymphoma patients.	MYD88
32323419	10.1111/pin.12937	2020	Composite monoclonal B-cell lymphocytosis and MYD88 L265P-positive lymphoplasmacytic lymphoma in a patient with IgM light chain amyloidosis: Case report.	MYD88
32325488	10.1182/blood.2019002654	2020	LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells.	MYD88
32335928	10.1111/cup.13722	2020	An unusual case of cutaneous Waldenström macroglobulinemia with the MYD88 L265P mutation.	MYD88
32374309	10.1039/d0fo00019a	2020	Dietary supplementation of l-arginine and N-carbamylglutamate enhances duodenal barrier and mitochondrial functions and suppresses duodenal inflammation and mitophagy in suckling lambs suffering from intrauterine-growth-restriction.	MYD88
32391356	10.3389/fcell.2020.00262	2020	A Dual TLR7/TLR9 Inhibitor HJ901 Inhibits ABC-DLBCL Expressing the MyD88 L265P Mutation.	MYD88
32399964	10.1002/ijc.33049	2020	Molecular profiling of Chinese R-CHOP treated DLBCL patients: Identifying a high-risk subgroup.	MYD88
32468019	10.3892/mmr.2020.11186	2020	Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.	MYD88
32469082	10.1002/cncr.32866	2020	Genome-defined African ancestry is associated with distinct mutations and worse survival in patients with diffuse large B-cell lymphoma.	MYD88
32488284	10.2340/00015555-3535	2020	Cutaneous Involvement in Waldenström's Macroglobulinaemia.	MYD88
32510610	10.1002/hon.2761	2020	On point in primary CNS lymphoma.	MYD88
32536998	10.3892/etm.2020.8695	2020	Effectiveness of digital PCR for MYD88<sup>L265P</sup> detection in vitreous fluid for primary central nervous system lymphoma diagnosis.	MYD88
32566435	10.7759/cureus.8651	2020	Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type: A Case Report.	MYD88
32572944	10.26355/eurrev_202006_21545	2020	Propofol improves intestinal ischemia-reperfusion injury in rats through NF-κB pathway.	MYD88
32578872	10.1111/bjh.16917	2020	Two independent consecutive lymphoma cases carry an identical MYD88 mutation but differ in their IGVH rearrangement.	MYD88
32603202	10.1080/14656566.2020.1770727	2020	An evaluation of Ibrutinib for the treatment of Waldenstrom macroglobulinaemia.	MYD88
32630470	10.3390/cancers12061688	2020	Immunoglobulin M Paraproteinaemias.	MYD88
32654665	10.1186/s13256-020-02404-x	2020	Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.	MYD88
32660905	10.1016/j.clml.2020.06.006	2020	Light Chain Deposition Disease in a Patient With MYD88 L265P Mutation-positive Low-grade B-cell Lymphoma and Monoclonal Immunoglobulin G κ.	MYD88
32695560	10.2176/nmccrj.cr.2019-0241	2020	Primary Central Nervous System Methotrexate-associated Lymphoproliferative Disorder in a Patient with Rheumatoid Arthritis: Case Report and Review of Literature.	MYD88
32723621	10.1016/j.clml.2020.06.025	2020	Monitoring Plasma Cell Dyscrasias With Cell-free DNA Analysis.	MYD88
32736575	10.1186/s12885-020-07198-1	2020	Novel bioinformatic classification system for genetic signatures identification in diffuse large B-cell lymphoma.	MYD88
32738175	10.1002/hon.2784	2020	Targeted next-generation sequencing reveals molecular heterogeneity in non-chronic lymphocytic leukemia clonal B-cell lymphocytosis.	MYD88
32745612	10.1016/j.jmoldx.2020.07.002	2020	Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.	MYD88
32780869	10.1111/bjh.17038	2020	Indolent clinical behaviour of primary cutaneous diffuse large B-cell lymphoma, leg type, with double MYC and BCL6 gene rearrangement.	MYD88
32781214	10.1016/j.leukres.2020.106426	2020	MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.	MYD88
32789566	10.1007/s12185-020-02970-2	2020	Lymphoplasmacytic lymphoma in a patient with Birt-Hogg-Dubé syndrome.	MYD88
32790920	10.1111/bjh.17036	2020	Direct-acting antiviral agents for hepatitis C virus-mixed cryoglobulinaemia: dissociated virological and haematological responses.	MYD88
32848129	10.1038/s41408-020-00351-w	2020	Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features.	MYD88
32854650	10.1186/s12885-020-07293-3	2020	DLBCL with amplification of JAK2/PD-L2 exhibits PMBCL-like CNA pattern and worse clinical outcome resembling those with MYD88 L265P mutation.	MYD88
32858764	10.1111/jcmm.15774	2020	IKKε and TBK1 in diffuse large B-cell lymphoma: A possible mechanism of action of an IKKε/TBK1 inhibitor to repress NF-κB and IL-10 signalling.	MYD88
32888499	10.1016/j.chembiol.2020.08.010	2020	Assessing IRAK4 Functions in ABC DLBCL by IRAK4 Kinase Inhibition and Protein Degradation.	MYD88
32932517	10.1182/blood.2020005857	2020	The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs.	MYD88
32947237	10.1016/j.tranon.2020.100855	2020	Identification of clinical molecular targets for childhood Burkitt lymphoma.	MYD88
32955949	10.1080/14728214.2020.1822816	2020	Emerging drugs for the treatment of Waldenström macroglobulinemia.	MYD88
32971631	10.4103/ijo.IJO_1712_19	2020	<i>MYD88</i> L265P mutation in intraocular lymphoma: A potential diagnostic marker.	MYD88
33050534	10.3390/cancers12102913	2020	Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice.	MYD88
33067267	10.1158/0008-5472.CAN-20-2425	2020	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma.	MYD88
33091850	10.1016/j.bmc.2020.115815	2020	Improving metabolic stability and removing aldehyde oxidase liability in a 5-azaquinazoline series of IRAK4 inhibitors.	MYD88
33154951	10.3389/fonc.2020.591577	2020	Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies.	MYD88
33180881	10.1371/journal.pone.0241634	2020	Lymphoplasmacytic lymphoma associated with diffuse large B-cell lymphoma: Progression or divergent evolution?	MYD88
33182056	10.1016/j.intimp.2020.106974	2020	Echinacea polysaccharide alleviates LPS-induced lung injury via inhibiting inflammation, apoptosis and activation of the TLR4/NF-κB signal pathway.	MYD88
33188997	10.1016/j.ctarc.2020.100235	2020	Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study.	MYD88
33211828	10.1182/bloodadvances.2020002944	2020	Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease.	MYD88
33214835	10.1021/acsmedchemlett.0c00378	2020	Discovery of a Selective, Covalent IRAK1 Inhibitor with Antiproliferative Activity in MYD88 Mutated B-Cell Lymphoma.	MYD88
33252851	10.1002/ctm2.221	2020	Influence of oncogenic mutations and tumor microenvironment alterations on extranodal invasion in diffuse large B-cell lymphoma.	MYD88
33275726	10.1182/hematology.2020000121	2020	Management of Waldenström macroglobulinemia in 2020.	MYD88
33297772	10.1080/17474086.2020.1851184	2020	Zanubrutinib for the treatment of Waldenström Macroglobulinemia.	MYD88
33318921	10.1016/j.rmcr.2020.101313	2020	Lymphoplasmacytic lymphoma involving the mediastinum and the lung, followed by amyloidosis: A surgically and genetically proven case.	MYD88
33343574	10.3389/fimmu.2020.602868	2020	B-Cell-Specific Myd88 L252P Expression Causes a Premalignant Gammopathy Resembling IgM MGUS.	MYD88
33445850	10.3760/cma.j.issn.0253-2727.2020.12.009	2020	[Clinical characteristics and prognosis of Waldenström's macroglobulinemia: a clinical data report from a single center].	MYD88
34667996	10.21037/aol-20-20	2020	Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond.	MYD88
29734251	10.1097/PAI.0000000000000585	2019	MYD88, CARD11, and CD79B Oncogenic Mutations are Rare Events in the Indian Cohort of De Novo Nodal Diffuse Large B-Cell Lymphoma.	MYD88
30038380	10.1038/s41375-018-0215-9	2019	Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.	MYD88
30113125	10.1111/aos.13808	2019	Clinical spectrum of vitreoretinal lymphoma and its association with MyD88 L265P mutation.	MYD88
30198568	10.1111/bjh.15584	2019	CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiation.	MYD88
30204732	10.1097/IAE.0000000000002319	2019	MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.	MYD88
30324684	10.1002/jcb.27854	2019	Protective effects and mechanism of curcumin on myocardial injury induced by coronary microembolization.	MYD88
30328142	10.1002/ajh.25292	2019	Waldenström macroglobulinemia: 2019 update on diagnosis, risk stratification, and management.	MYD88
30338525	10.1111/bjh.15610	2019	Genetic analysis of Diffuse Large B-cell Lymphoma occurring in cases with antecedent Waldenström Macroglobulinaemia reveals different patterns of clonal evolution.	MYD88
30342054	10.1016/j.humpath.2018.09.021	2019	Prolymphocytic transformation of lymphoplasmacytic lymphoma: an extremely unusual event.	MYD88
30353605	10.1111/cas.13848	2019	Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.	MYD88
30360939	10.1016/j.leukres.2018.10.003	2019	Immunohistochemical distinction of ABC and GCB in extranodal DLBCL is not reflected in mutation patterns.	MYD88
30390359	10.1111/ejh.13191	2019	CD79B mutations in primary vitreoretinal lymphoma: Diagnostic and prognostic potential.	MYD88
30408153	10.1111/bjh.15674	2019	MYD88 p.(L265P) detection on cell-free DNA in liquid biopsies of patients with primary central nervous system lymphoma.	MYD88
30426157	10.1007/s00277-018-3545-9	2019	Uncommon lymphoplasmacytic lymphoma with IgA paraproteinemia: a challenging clinical diagnosis solved by MYD88 mutation analysis.	MYD88
30444439	10.5858/arpa.2018-0092-OA	2019	High Frequency of MYD88 L265P Mutation in Primary Ocular Adnexal Marginal Zone Lymphoma and Its Clinicopathologic Correlation: A Study From a Single Institution.	MYD88
30501537	10.1080/10428194.2018.1537487	2019	Modulating the conformation of the TIR domain by a neoteric MyD88 inhibitor leads to the separation of GVHD from GVT.	MYD88
30604315	10.1007/s12185-018-02585-8	2019	Is clinicopathological distinction of mucosa-associated lymphoid tissue lymphoma from Waldenström macroglobulinemia essential in MYD88 L265P mutation-positive cases?	MYD88
30608918	10.12659/MSM.912490	2019	Protective Effect of Hesperidin Against Sepsis-Induced Lung Injury by Inducing the Heat-Stable Protein 70 (Hsp70)/Toll-Like Receptor 4 (TLR4)/ Myeloid Differentiation Primary Response 88 (MyD88) Pathway.	MYD88
30623224	10.1007/s00347-018-0840-8	2019	[New molecular pathological strategies for malignant iris tumors].	MYD88
30663686	10.3791/58439	2019	Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity.	MYD88
30680453	10.1007/s00428-019-02527-7	2019	AL amyloidosis with a localized B cell neoplasia.	MYD88
30683910	10.1038/s41375-019-0380-5	2019	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas.	MYD88
30715765	10.1111/his.13832	2019	Primary cutaneous large B-cell lymphomas: relevance of the 2017 World Health Organization classification: clinicopathological and molecular analyses of 64 cases.	MYD88
30723112	10.1182/bloodadvances.2018027672	2019	<i>MYD88</i> L265P mutation and <i>CDKN2A</i> loss are early mutational events in primary central nervous system diffuse large B-cell lymphomas.	MYD88
30763982	10.1111/bjh.15792	2019	Digital PCR in bone marrow trephine biopsies is highly sensitive for MYD88<sup>L265P</sup> detection in lymphomas with plasmacytic/plasmacytoid differentiation.	MYD88
30772517	10.1016/j.gene.2019.02.030	2019	The inhibition of microRNA-203 on ischemic reperfusion injury after total knee arthroplasty via suppressing MYD88-mdiated toll-like receptor signaling pathway.	MYD88
30793105	10.1016/j.htct.2018.05.014	2019	Prognostic impact of <i>MYD88</i> mutation, proliferative index and cell origin in diffuse large B cell lymphoma.	MYD88
30815927	10.1111/cas.13983	2019	Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan.	MYD88
30828149	10.1007/s12288-018-0978-1	2019	MYD88 and CXCR4 Mutation Profiling in Lymphoplasmacytic Lymphoma/Waldenstrom's Macroglobulinaemia.	MYD88
30989098	10.1016/j.jdcr.2019.02.002	2019	Schnitzler syndrome associated with <i>MYD88</i> L265P mutation.	MYD88
31000522	10.1158/0008-5472.CAN-18-3438	2019	MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma.	MYD88
31033057	10.1111/cyt.12711	2019	Cytological diagnosis of vitreoretinal lymphomas: A case series.	MYD88
31107988	10.1111/his.13921	2019	MYD88L265P mutated IgA lymphoplasmacytic lymphoma.	MYD88
31109360	10.1186/s13000-019-0826-0	2019	Rare cases of primary central nervous system anaplastic variant of diffuse large B-cell lymphoma.	MYD88
31115023	10.26355/eurrev_201905_17824	2019	A study of regulatory effects of TLR4 and NF-κB on primary biliary cholangitis.	MYD88
31150604	10.1016/j.jid.2019.05.008	2019	Mutations of the B-Cell Receptor Pathway Confer Chemoresistance in Primary Cutaneous Diffuse Large B-Cell Lymphoma Leg Type.	MYD88
31184237	10.1080/10428194.2019.1620942	2019	Clinicopathologic correlates of <i>MYD88</i> L265P mutation and programmed cell death (PD-1) pathway in primary central nervous system lymphoma.	MYD88
31202483	10.1016/j.pathol.2019.03.005	2019	MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenström macroglobulinaemia.	MYD88
31221512	10.1016/j.clml.2019.03.009	2019	Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing.	MYD88
31229160	10.1016/j.hoc.2019.03.004	2019	Lymphoplasmacytic Lymphoma and Marginal Zone Lymphoma.	MYD88
31243026	10.1136/bcr-2019-230067	2019	Rare case of Bing-Neel syndrome treated successfully with ibrutinib.	MYD88
31255931	10.1016/j.jss.2019.05.036	2019	Posttreatment With LYRM03 Protects Rats From Acute Lung Inflammation Induced by Lipopolysaccharide via Suppressing the NF-κB/MyD88/TLR4 Axis.	MYD88
31276195	10.1111/bjh.16086	2019	A risk-stratification model based on the initial concentration of the serum monoclonal protein and MYD88 mutation status identifies a subset of patients with IgM monoclonal gammopathy of undetermined significance at high risk of progression to Waldenström macroglobulinaemia or other lymphoproliferative disorders.	MYD88
31278738	10.1093/ajcp/aqz078	2019	Molecular Genetics in the Diagnosis and Biology of Lymphoid Neoplasms.	MYD88
31292111	10.1182/blood.2019000022	2019	Single-cell MYD88 sequencing of isolated B cells from vitreous biopsies aids vitreoretinal lymphoma diagnosis.	MYD88
31305194	10.1080/10428194.2019.1639169	2019	Comparison of circulating tumor DNA between body fluids in patients with primary central nervous system lymphoma.	MYD88
31378966	10.1002/ajh.25600	2019	Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.	MYD88
31391404	10.3960/jslrt.19009	2019	IgA-producing lymphoplasmacytic lymphoma carrying the chromosomal abnormality t(8;14).	MYD88
31402495	10.1111/imr.12792	2019	Pathogenic B-cell receptor signaling in lymphoid malignancies: New insights to improve treatment.	MYD88
31403034	10.3389/fonc.2019.00683	2019	Comprehensive Genomic Profiling of EBV-Positive Diffuse Large B-cell Lymphoma and the Expression and Clinicopathological Correlations of Some Related Genes.	MYD88
31432184	10.3892/or.2019.7282	2019	Disrupting myddosome assembly in diffuse large B‑cell lymphoma cells using the MYD88 dimerization inhibitor ST2825.	MYD88
31436356	10.1111/cas.14176	2019	Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.	MYD88
31464711	10.1097/PAS.0000000000001363	2019	Class-switched Primary Cutaneous Marginal Zone Lymphomas Are Frequently IgG4-positive and Have Features Distinct From IgM-positive Cases.	MYD88
31484887	10.11406/rinketsu.60.903	2019	[Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].	MYD88
31488111	10.1186/s12906-019-2656-8	2019	The protective effect and mechanism of catalpol on high glucose-induced podocyte injury.	MYD88
31527073	10.1182/blood.2019000725	2019	How I treat Waldenström macroglobulinemia.	MYD88
31528323	10.4084/MJHID.2019.057	2019	Response to Ibrutinib of a Refractory IgA Lymphoplasmacytic Lymphoma Carrying the <i>MYD88</i> L265P Gene Mutation.	MYD88
31556196	10.1111/pin.12854	2019	MYD88 L265P mutation analysis is a useful diagnostic adjunct for lymphoplasmacytic lymphoma with pleural effusion.	MYD88
31576141	10.2147/OTT.S211436	2019	Follicular Lymphoma Presenting With Monoclonal IgM And MYD88 Mutation: A Case Report And Review Of The Literature.	MYD88
31589186	10.1097/ICU.0000000000000620	2019	Primary vitreoretinal lymphoma: empowering our clinical suspicion.	MYD88
31591468	10.1038/s41375-019-0592-8	2019	What is new in the treatment of Waldenstrom macroglobulinemia?	MYD88
31592789	10.1097/WCO.0000000000000759	2019	Molecular profiling of primary central nervous system lymphomas - predictive and prognostic value?	MYD88
31695539	10.2147/JBM.S183997	2019	Evaluating ibrutinib in the treatment of symptomatic Waldenstrom's macroglobulinemia.	MYD88
31698464	10.1182/bloodadvances.2019000588	2019	Human MYD88L265P is insufficient by itself to drive neoplastic transformation in mature mouse B cells.	MYD88
31699794	10.3324/haematol.2019.227272	2019	MYD88 in the driver's seat of B-cell lymphomagenesis: from molecular mechanisms to clinical implications.	MYD88
31806993	10.2147/OTT.S227122	2019	Genomic Alterations In Primary Cardiac Diffuse Large B Cell Lymphoma: A Case Report And Literature Review.	MYD88
32063711	10.2147/OTT.S222189	2019	Prevalence And Clinical Significance Of Oncogenic <i>CD79B</i> And <i>MYD88</i> Mutations In Primary Testicular Diffuse Large B-Cell Lymphoma: A Retrospective Study In China.	MYD88
35100686	10.1200/PO.18.00308	2019	High Detection Rate of <i>MYD88</i> Mutations in Cerebrospinal Fluid From Patients With CNS Lymphomas.	MYD88
28815730	10.1002/jcb.26353	2018	Loss of BMI-1 dampens migration and EMT of colorectal cancer in inflammatory microenvironment through TLR4/MD-2/MyD88-mediated NF-κB signaling.	MYD88
28868954	10.1080/10428194.2017.1370546	2018	Mutational frequencies of CD79B and MYD88 vary greatly between primary testicular DLBCL and gastrointestinal DLBCL.	MYD88
29018161	10.1136/jnnp-2017-316689	2018	High prevalence of the <i>MYD88 L265P</i> mutation in IgM anti-MAG paraprotein-associated peripheral neuropathy.	MYD88
29043881	10.1080/10428194.2017.1387903	2018	Characterization of the mutational profile of 11 diffuse large B-cell lymphoma cell lines.	MYD88
29080258	10.1002/ajh.24955	2018	MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.	MYD88
29122821	10.1136/bjophthalmol-2017-311151	2018	Metagenomic deep sequencing of aqueous fluid detects intraocular lymphomas.	MYD88
29151258	10.1111/cas.13450	2018	Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.	MYD88
29181840	10.1111/bjh.15049	2018	MYD88 wild-type Waldenstrom Macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival.	MYD88
29210102	10.1002/hon.2489	2018	The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.	MYD88
29258950	10.1016/j.wneu.2017.12.028	2018	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.	MYD88
29289361	10.1016/j.blre.2017.12.001	2018	The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.	MYD88
29358175	10.1182/blood-2017-09-805499	2018	Extracellular vesicle-mediated transfer of constitutively active MyD88<sup>L265P</sup> engages MyD88<sup>wt</sup> and activates signaling.	MYD88
29375693	10.3892/etm.2017.5349	2018	Simvastatin improves intracerebral hemorrhage through NF-κB-mediated apoptosis via the MyD88/TRIF signaling pathway.	MYD88
29398441	10.1016/j.bmc.2018.01.008	2018	Optimization of permeability in a series of pyrrolotriazine inhibitors of IRAK4.	MYD88
29403563	10.3892/ol.2017.7472	2018	High frequency and prognostic value of <i>MYD88</i> L265P mutation in diffuse large B-cell lymphoma with R-CHOP treatment.	MYD88
29433938	10.1016/j.ymthe.2018.01.007	2018	B Cell Lymphoma Immunotherapy Using TLR9-Targeted Oligonucleotide STAT3 Inhibitors.	MYD88
29482770	10.1016/j.jmoldx.2017.11.006	2018	MYD88 Mutations and Sensitivity to Ibrutinib Therapy.	MYD88
29496671	10.1182/blood-2017-10-811752	2018	BTK<sup>Cys481Ser</sup> drives ibrutinib resistance via ERK1/2 and protects BTK<sup>wild-type</sup> MYD88-mutated cells by a paracrine mechanism.	MYD88
29514783	10.1182/blood-2017-12-822817	2018	High prevalence of <i>MYD88</i> and <i>CD79B</i> mutations in intravascular large B-cell lymphoma.	MYD88
29567768	10.3324/haematol.2017.186528	2018	Highly sensitive <i>MYD88</i><sup>L265P</sup> mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia.	MYD88
29587428	10.3390/biomedicines6020038	2018	NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy.	MYD88
29596904	10.1016/j.jid.2018.03.1516	2018	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type.	MYD88
29610969	10.1007/s00277-018-3311-z	2018	Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.	MYD88
29637541	10.1111/bjh.15202	2018	How we manage patients with Waldenström macroglobulinaemia.	MYD88
29641966	10.1056/NEJMoa1801445	2018	Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.	MYD88
29703722	10.1158/0008-5472.CAN-18-0215	2018	<i>MYD88</i> L265P Mutation in Lymphoid Malignancies.	MYD88
29712895	10.1038/s41408-018-0076-5	2018	Waldenström macroglobulinemia treatment algorithm 2018.	MYD88
29760948	10.1186/s40942-018-0120-4	2018	The diagnosis and treatment of primary vitreoretinal lymphoma: a review.	MYD88
29856685	10.1056/NEJMoa1802917	2018	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.	MYD88
29857068	10.1016/j.jid.2018.04.038	2018	Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.	MYD88
29868855	10.1093/ajcp/aqy041	2018	Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?	MYD88
29869471	10.30637/2018.17-090	2018	[Diagnostic approach of an IgM monoclonal gammopathy and clinical importance of gene MYD88 L265P mutation].	MYD88
29871863	10.1182/blood-2017-12-819706	2018	HSP110 sustains chronic NF-κB signaling in activated B-cell diffuse large B-cell lymphoma through MyD88 stabilization.	MYD88
29878045	10.1093/annonc/mdy133	2018	Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	MYD88
29891112	10.1016/j.critrevonc.2018.05.010	2018	Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.	MYD88
29895903	10.1038/s41408-018-0089-0	2018	Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay.	MYD88
29899297	10.3390/ijms19061758	2018	Molecular Mechanisms of Disease Progression in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type during Ibrutinib Therapy.	MYD88
29925955	10.1038/s41586-018-0290-0	2018	A multiprotein supercomplex controlling oncogenic signalling in lymphoma.	MYD88
29931605	10.1007/s11864-018-0555-8	2018	Extranodal Diffuse Large B Cell Lymphoma: Molecular Features, Prognosis, and Risk of Central Nervous System Recurrence.	MYD88
29937999	10.18632/oncotarget.25463	2018	Target amplicon exome-sequencing identifies promising diagnosis and prognostic markers involved in RTK-RAS and PI3K-AKT signaling as central oncopathways in primary central nervous system lymphoma.	MYD88
29957733	10.1097/PAS.0000000000001113	2018	Expanding the Spectrum of EBV-positive Marginal Zone Lymphomas: A Lesion Associated With Diverse Immunodeficiency Settings.	MYD88
29973445	10.11406/rinketsu.59.695	2018	[Successful diagnosis of lymphoplasmacytic lymphoma with IgG paraprotein using MYD88 L265P mutation analysis].	MYD88
29982402	10.1093/annonc/mdy146	2018	Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.	MYD88
29989027	10.18632/oncotarget.25601	2018	New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes.	MYD88
30027272	10.1001/jamaophthalmol.2018.2887	2018	Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.	MYD88
30027276	10.1001/jamaophthalmol.2018.2894	2018	Detection of MYD88 Mutations in Vitreoretinal Lymphoma and Its Implications.	MYD88
30072412	10.1182/blood-2018-06-857532	2018	HSP110 and MYD88: blame the chaperone.	MYD88
30086464	10.1016/j.biopha.2018.07.139	2018	Dual functional roles of the MyD88 signaling in colorectal cancer development.	MYD88
30126942	10.1158/1078-0432.CCR-17-3265	2018	Targeting Myddosome Signaling in Waldenström's Macroglobulinemia with the Interleukin-1 Receptor-Associated Kinase 1/4 Inhibitor R191.	MYD88
30171453	10.1007/s11060-018-2990-6	2018	Characterization of genomic alterations in primary central nervous system lymphomas.	MYD88
30190015	10.1016/j.hoc.2018.05.007	2018	Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.	MYD88
30203262	10.1007/s00262-018-2242-9	2018	Oncogenic MYD88 mutations in lymphoma: novel insights and therapeutic possibilities.	MYD88
30227305	10.1016/j.neo.2018.08.012	2018	Analysis of Genomic Alteration in Primary Central Nervous System Lymphoma and the Expression of Some Related Genes.	MYD88
30238920	10.1684/abc.2018.1384	2018	IgG lymphoplasmacytic lymphoma: a case report.	MYD88
30253331	10.1016/j.intimp.2018.09.024	2018	MYD88 L265P mutation promoted malignant B cell resistance against T cell-mediated cytotoxicity via upregulating the IL-10/STAT3 cascade.	MYD88
30294590	10.3389/fonc.2018.00382	2018	Detection of the <i>MYD88</i> p.L265P Mutation in the CSF of a Patient With Secondary Central Nervous System Lymphoma.	MYD88
30301877	10.1038/s41408-018-0130-3	2018	Loss of TNFAIP3 enhances MYD88<sub>L265P</sub>-driven signaling in non-Hodgkin lymphoma.	MYD88
30360879	10.1053/j.seminoncol.2018.07.005	2018	New concepts in follicular lymphoma biology: From BCL2 to epigenetic regulators and non-coding RNAs.	MYD88
30401751	10.1182/bloodadvances.2018022962	2018	Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia.	MYD88
30429379	10.1172/jci.insight.125568	2018	Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.	MYD88
30501701	10.7534/j.issn.1009-2137.2018.06.014	2018	[ARMS-PCR combined with capillary electrophoresis can be a sensitive and quantitative method for detection of MYD88-L265P mutation in lymphoma].	MYD88
30626796	10.11406/rinketsu.59.2600	2018	[MALT lymphoma accompanied by elevated serum IgM levels mimicking Waldenström's macroglobulinemia].	MYD88
27161435	10.1111/bjh.14080	2017	MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.	MYD88
27347751	10.1080/10428194.2016.1196813	2017	Splenic diffuse red pulp lymphoma has a distinct pattern of somatic mutations amongst B-cell malignancies.	MYD88
27687087	10.1080/10428194.2016.1213836	2017	Nodal marginal zone lymphoma: mutation status analyses of CD79A, CD79B, and MYD88 reveal no specific recurrent lesions.	MYD88
27734522	10.1002/hon.2361	2017	Detection of L265P MYD-88 mutation in a series of clonal B-cell lymphocytosis of marginal zone origin (CBL-MZ).	MYD88
27840426	10.1038/leu.2016.330	2017	Genetic characterization of MYD88-mutated lymphoplasmacytic lymphoma in comparison with MYD88-mutated chronic lymphocytic leukemia.	MYD88
27861728	10.1111/bjd.15183	2017	Myeloid differentiation primary response 88 mutations in a distinct type of cutaneous marginal-zone lymphoma with a nonclass-switched immunoglobulin M immunophenotype.	MYD88
27915469	10.1002/cncr.30404	2017	MYD88, CD79B, and CARD11 gene mutations in CD5-positive diffuse large B-cell lymphoma.	MYD88
27923841	10.1158/1078-0432.CCR-16-1922	2017	Biological and Clinical Relevance of Associated Genomic Alterations in MYD88 L265P and non-L265P-Mutated Diffuse Large B-Cell Lymphoma: Analysis of 361 Cases.	MYD88
28002793	10.18632/oncotarget.14008	2017	Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies.	MYD88
28042684	10.1111/ijlh.12598	2017	Detection of the MYD88 mutation by the combination of the allele-specific PCR and quenching probe methods.	MYD88
28056114	10.1001/jamaoncol.2016.5763	2017	Diagnosis and Management of Waldenström Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016.	MYD88
28073005	10.1016/j.ccell.2016.12.003	2017	Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT.	MYD88
28076910	10.1111/imj.13311	2017	Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group.	MYD88
28094456	10.1002/ajh.24557	2017	Waldenström macroglobulinemia: 2017 update on diagnosis, risk stratification, and management.	MYD88
28147336	10.18632/oncotarget.14876	2017	Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.	MYD88
28153771	10.1016/j.ebiom.2017.01.027	2017	B-cell Function Gene Mutations in Diffuse Large B-cell Lymphoma: A Retrospective Cohort Study.	MYD88
28232371	10.3324/haematol.2016.156281	2017	c-Myc dysregulation is a co-transforming event for nuclear factor-κB activated B cells.	MYD88
28235842	10.1182/blood-2017-01-761726	2017	Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.	MYD88
28241765	10.1186/s12967-017-1152-5	2017	Heterogeneity of Toll-like receptor 9 signaling in B cell malignancies and its potential therapeutic application.	MYD88
28273183		2017	[The pathology and genetic background of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia].	MYD88
28280994	10.1007/s00277-017-2968-z	2017	Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.	MYD88
28286680	10.1155/2017/5183646	2017	Utility of MYD88 in the Differential Diagnosis and Choice of Second-Line Therapy in a Case of Nonsecretory Lymphoplasmacytic Lymphoma versus Free Light Chain Waldenstrom's Macroglobulinemia.	MYD88
28319526	10.1097/PAS.0000000000000836	2017	Anaplastic Variant of Diffuse Large B-cell Lymphoma Displays Intricate Genetic Alterations and Distinct Biological Features.	MYD88
28321094	10.11406/rinketsu.58.155	2017	Lymphoplasmacytic lymphoma accompanied by transformed diffuse large B-cell lymphoma with the MYD88<sup>L265P</sup> mutation.	MYD88
28331368	10.2147/CMAR.S94059	2017	New developments in the management of Waldenström macroglobulinemia.	MYD88
28341730	10.3324/haematol.2016.161893	2017	Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant <i>MYD88</i> and wildtype <i>CD79</i>.	MYD88
28352655	10.1172/jci.insight.90196	2017	Panobinostat acts synergistically with ibrutinib in diffuse large B cell lymphoma cells with MyD88 L265P mutations.	MYD88
28366781	10.1016/j.clml.2017.02.028	2017	Waldenström Macroglobulinemia: Review of Pathogenesis and Management.	MYD88
28368397	10.1038/onc.2017.90	2017	Molecular impact of selective NFKB1 and NFKB2 signaling on DLBCL phenotype.	MYD88
28370087	10.1111/cup.12944	2017	MYD88 L265P mutation in cutaneous involvement by Waldenström macroglobulinemia.	MYD88
28381754	10.2169/internalmedicine.56.7340	2017	Lymphoplasmacytic Lymphoma Presenting with Diarrhea and Joint Pain Which was Successfully Diagnosed by an MYD88 Mutation Analysis.	MYD88
28405493	10.1080/2162402X.2016.1219825	2017	HLA class I-restricted <i>MYD88</i> L265P-derived peptides as specific targets for lymphoma immunotherapy.	MYD88
28479318	10.1016/j.jid.2017.04.010	2017	Identification of Somatic Mutations in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type by Massive Parallel Sequencing.	MYD88
28483372	10.1016/j.pathol.2017.02.004	2017	Role of plasma cells in Waldenström macroglobulinaemia.	MYD88
28496180	10.1038/s41598-017-01998-5	2017	Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysis.	MYD88
28533926		2017	Concomitant lymphoplasmacytic lymphoma and plasma cell myeloma, a diagnostic challenge.	MYD88
28552327	10.1016/j.ccell.2017.04.012	2017	Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.	MYD88
28558176	10.22608/APO.2017150	2017	Primary Vitreoretinal Lymphoma -- A Review.	MYD88
28592763	10.11406/rinketsu.58.480	2017	Malignant lymphoma: pathophysiology and current therapy.	MYD88
28617062	10.1080/17474086.2017.1343661	2017	Novel approaches to targeting MYD88 in Waldenström macroglobulinemia.	MYD88
28636991	10.18632/oncotarget.18325	2017	Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.	MYD88
28664939	10.1038/modpathol.2017.58	2017	Clinical utility of recently identified diagnostic, prognostic, and predictive molecular biomarkers in mature B-cell neoplasms.	MYD88
28679988	10.11406/rinketsu.58.595	2017	Follicular lymphoma with plasmacytic differentiation accompanied by monoclonal IgG gammopathy.	MYD88
28682481	10.1002/path.4933	2017	Significant association between TNFAIP3 inactivation and biased immunoglobulin heavy chain variable region 4-34 usage in mucosa-associated lymphoid tissue lymphoma.	MYD88
28690525	10.1159/000477489	2017	Primary Type3 (Non-ABC, Non-GCB) Subtype of Extranodal Diffuse Large B-Cell Lymphoma of the Thyroid Bearing No <i>MYD88</i> Mutation by Padlock Probe Hybridization.	MYD88
28701369	10.1084/jem.20161454	2017	Synergistic cooperation and crosstalk between <i>MYD88<sup>L265P</sup></i> and mutations that dysregulate CD79B and surface IgM.	MYD88
28751561	10.3324/haematol.2016.160192	2017	Exome sequencing identifies recurrent <i>BCOR</i> alterations and the absence of <i>KLF2</i>, <i>TNFAIP3</i> and <i>MYD88</i> mutations in splenic diffuse red pulp small B-cell lymphoma.	MYD88
28786474	10.1111/bjh.14826	2017	Dexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naïve patients with Waldenstrom macroglobulinemia.	MYD88
28803429	10.1007/s00277-017-3094-7	2017	Patients with primary breast and primary female genital tract diffuse large B cell lymphoma have a high frequency of MYD88 and CD79B mutations.	MYD88
28811957	10.1080/2162402X.2017.1321184	2017	Mapping the human T cell repertoire to recurrent driver mutations in MYD88 and EZH2 in lymphoma.	MYD88
28847710	10.1016/j.bbmt.2017.08.022	2017	Lack of a Prognostic Impact of the MyD88 L265P Mutation for Diffuse Large B Cell Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.	MYD88
28856744	10.1111/neup.12405	2017	Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.	MYD88
28877839	10.3881/j.issn.1000-503X.2017.04.019	2017	Significances of MYD88<sup>L265P</sup> and CXCR4<sup>WHIM</sup> Mutations in Waldenstrom Macroglobulinemia.	MYD88
28892161	10.1002/path.4982	2017	A gene is known by the company it keeps: enrichment of TNFAIP3 gene aberrations in MALT lymphomas expressing IGHV4-34 antigen receptors.	MYD88
28903575	10.14735/amko20172S81	2017	Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.	MYD88
28922238	10.1097/WCO.0000000000000492	2017	Primary central nervous system lymphoma: time for diagnostic biomarkers and biotherapies?	MYD88
28987624	10.1016/j.micpath.2017.10.004	2017	Toll like receptor 4 signaling pathway participated in Salmonella lipopolysaccharide-induced spleen injury in young chicks.	MYD88
28993276	10.1016/j.humpath.2017.09.013	2017	A distinctive subgroup of oral EBV+ B-cell neoplasm with polymorphous features is potentially identical to EBV+ mucocutaneous ulcer.	MYD88
28993856	10.1007/s00292-017-0378-6	2017	[Malignant lymphomas of the eye].	MYD88
29025291	10.1556/650.2017.30868	2017	[Waldenström's macroglobulinemia and its individualized therapy options].	MYD88
29029457	10.18632/oncotarget.19936	2017	Prognostic relevance of protein expression, clinical factors, and <i>MYD88</i> mutation in primary bone lymphoma.	MYD88
29054399	10.1016/j.jmoldx.2017.07.007	2017	Determination of Molecular Subtypes of Diffuse Large B-Cell Lymphoma Using a Reverse Transcriptase Multiplex Ligation-Dependent Probe Amplification Classifier: A CALYM Study.	MYD88
29061802	10.21873/anticanres.12070	2017	MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells.	MYD88
29070995	10.1159/000480292	2017	Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88<sup>L265P</sup> Mutation.	MYD88
29081197	10.3760/cma.j.issn.0253-2727.2017.09.011	2017	[Clinical features and prognosis of 17 patients with primary cold agglutinin disease].	MYD88
29088270	10.1371/journal.pone.0186614	2017	IRAK4 is essential for TLR9-induced suppression of Epstein-Barr virus BZLF1 transcription in Akata Burkitt's lymphoma cells.	MYD88
29172502	10.1021/acs.jmedchem.7b01290	2017	Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell Lymphoma.	MYD88
29222280	10.1182/asheducation-2017.1.365	2017	Toward personalized treatment in Waldenström macroglobulinemia.	MYD88
29245897	10.18632/oncotarget.18502	2017	Comparative analysis of primary <i>versus</i> relapse/refractory DLBCL identifies shifts in mutation spectrum.	MYD88
29262531	10.18632/oncotarget.21986	2017	Mutational profile of primary breast diffuse large B-cell lymphoma.	MYD88
32064225	10.1016/j.ehpc.2017.06.006	2017	Persistent indolent pancolonic marginal zone lymphoma of MALT-type with plasmacytic differentiation - A rare post-transplant lymphoma?	MYD88
26111727	10.1111/nan.12259	2016	Recurrent mutations of CD79B and MYD88 are the hallmark of primary central nervous system lymphomas.	MYD88
26747248	10.1182/blood-2015-07-655647	2016	CARMA1- and MyD88-dependent activation of Jun/ATF-type AP-1 complexes is a hallmark of ABC diffuse large B-cell lymphomas.	MYD88
26752547	10.1097/PAS.0000000000000592	2016	Frequent MYD88 L265P and CD79B Mutations in Primary Breast Diffuse Large B-Cell Lymphoma.	MYD88
26757737	10.1007/s00401-016-1536-2	2016	Genomic characterization of primary central nervous system lymphoma.	MYD88
26773040	10.1182/blood-2015-09-672352	2016	Diffuse large B-cell lymphoma patient-derived xenograft models capture the molecular and biological heterogeneity of the disease.	MYD88
26787899	10.1073/pnas.1524677113	2016	Subtype-specific addiction of the activated B-cell subset of diffuse large B-cell lymphoma to FOXP1.	MYD88
26792260	10.1158/1078-0432.CCR-15-1525	2016	MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome.	MYD88
26797804	10.1111/ijlh.12456	2016	Positive selection and high sensitivity test for MYD88 mutations using locked nucleic acid.	MYD88
26800678	10.1007/s00108-015-0006-6	2016	[Classification of malignant lymphomas. Current situation].	MYD88
26841176	10.1055/s-0041-107960	2016	[New developments in Waldenström's macroglobulinemia].	MYD88
26867669	10.1038/leu.2016.8	2016	Clonal B cells in Waldenström's macroglobulinemia exhibit functional features of chronic active B-cell receptor signaling.	MYD88
26883583	10.3109/10428194.2016.1139703	2016	Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.	MYD88
26900675	10.1097/IAE.0000000000000996	2016	PREVALENCE OF MYD88 L265P MUTATION IN HISTOLOGICALLY PROVEN, DIFFUSE LARGE B-CELL VITREORETINAL LYMPHOMA.	MYD88
26942591	10.1007/s11864-016-0391-7	2016	Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.	MYD88
26980069	10.3109/10428194.2016.1157875	2016	Response to ibrutinib in a patient with IgG lymphoplasmacytic lymphoma carrying the MYD88 L265P gene mutation.	MYD88
27048211	10.1182/blood-2015-11-684183	2016	B-cell-specific conditional expression of Myd88p.L252P leads to the development of diffuse large B-cell lymphoma in mice.	MYD88
27102345	10.1038/modpathol.2016.79	2016	Comprehensive genomic profiling of orbital and ocular adnexal lymphomas identifies frequent alterations in MYD88 and chromatin modifiers: new routes to targeted therapies.	MYD88
27121112	10.3109/10428194.2016.1173212	2016	Genetic aberrations in small B-cell lymphomas and leukemias: molecular pathology, clinical relevance and therapeutic targets.	MYD88
27143257	10.1182/blood-2016-01-695098	2016	HCK is a survival determinant transactivated by mutated MYD88, and a direct target of ibrutinib.	MYD88
27189828	10.1016/j.jid.2016.04.018	2016	MYD88 Somatic Mutation Is a Diagnostic Criterion in Primary Cutaneous Large B-Cell Lymphoma.	MYD88
27198204	10.1038/leu.2016.135	2016	Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.	MYD88
27262792	10.1016/j.semcancer.2016.05.002	2016	Mechanisms of NF-κB deregulation in lymphoid malignancies.	MYD88
27268124	10.1016/j.clml.2016.04.014	2016	Clinical Validation of a CXCR4 Mutation Screening Assay for Waldenstrom Macroglobulinemia.	MYD88
27329639	10.1093/ajcp/aqw072	2016	Lymphoplasmacytic Lymphoma With a Non-IgM Paraprotein Shows Clinical and Pathologic Heterogeneity and May Harbor MYD88 L265P Mutations.	MYD88
27402288	10.1016/j.semcancer.2016.07.001	2016	Toll-like receptors signaling: A complex network for NF-κB activation in B-cell lymphoid malignancies.	MYD88
27439595	10.1111/pin.12439	2016	Clinicopathological features of 49 primary gastrointestinal diffuse large B-cell lymphoma cases; comparison with location, cell-of-origin, and frequency of MYD88 L265P.	MYD88
27440511	10.1373/clinchem.2016.255315	2016	Multiplex Droplet Digital PCR Quantification of Recurrent Somatic Mutations in Diffuse Large B-Cell and Follicular Lymphoma.	MYD88
27452667	10.1016/j.semcancer.2016.07.003	2016	MALT lymphoma: A paradigm of NF-κB dysregulation.	MYD88
27458005	10.1182/blood-2016-03-708065	2016	Inhibiting TLR9 and other UNC93B1-dependent TLRs paradoxically increases accumulation of MYD88L265P plasmablasts in vivo.	MYD88
27503954	10.1093/protein/gzw033	2016	Conformational dynamics of cancer-associated MyD88-TIR domain mutant L252P (L265P) allosterically tilts the landscape toward homo-dimerization.	MYD88
27526684	10.1111/ejh.12792	2016	Rewired NFκB signaling as a potentially actionable feature of activated B-cell-like diffuse large B-cell lymphoma.	MYD88
27566587	10.18632/oncotarget.11548	2016	Recurrent mutations in NF-κB pathway components, KMT2D, and NOTCH1/2 in ocular adnexal MALT-type marginal zone lymphomas.	MYD88
27707672	10.1684/abc.2016.1179	2016	Cytogenetics in the management of lymphomas and lymphoproliferative disorders in adults and children: an update by the Groupe francophone de cytogénétique hématologique (GFCH).	MYD88
27722129	10.5045/br.2016.51.3.181	2016	Detection of MYD88 L265P in patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia and other B-cell non-Hodgkin lymphomas.	MYD88
27733371	10.1158/0008-5472.CAN-16-0504	2016	TLR Adaptor Protein MYD88 Mediates Sensitivity to HDAC Inhibitors via a Cytokine-Dependent Mechanism.	MYD88
27795509	10.11406/rinketsu.57.2013	2016	Diffuse large B-cell lymphoma: current standard treatment and future perspectives.	MYD88
27799566	10.1073/pnas.1610970113	2016	Epigenetic gene regulation by Janus kinase 1 in diffuse large B-cell lymphoma.	MYD88
27825110	10.18632/oncotarget.13065	2016	Mutations or copy number losses of CD58 and TP53 genes in diffuse large B cell lymphoma are independent unfavorable prognostic factors.	MYD88
27825459	10.1016/j.beha.2016.08.024	2016	Origin of Waldenstrom's macroglobulinaemia.	MYD88
27825467	10.1016/j.beha.2016.08.021	2016	Future therapeutic options for patients with Waldenström macroglobulinemia.	MYD88
27835906	10.18632/oncotarget.13239	2016	Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.	MYD88
27837631		2016	The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.	MYD88
27890075	10.1016/j.leukres.2016.10.008	2016	Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.	MYD88
27980305	10.3960/jslrt.56.71	2016	Molecular Pathogenesis of Diffuse Large B-Cell Lymphoma.	MYD88
28088969	10.3760/cma.j.issn.0253-2727.2016.12.009	2016	[The clinical features of patients with lymphoplasmacytic diseases harboring MyD88 L265P mutation].	MYD88
31360080	10.2147/BLCTT.S84157	2016	Waldenström macroglobulinemia: biology, genetics, and therapy.	MYD88
24828863	10.3109/10428194.2014.924123	2015	MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.	MYD88
25216226	10.1038/modpathol.2014.120	2015	MYD88 L265P mutation analysis helps define nodal lymphoplasmacytic lymphoma.	MYD88
25247317	10.1159/000358914	2015	Oncogenic MYD88 mutations are rare events in double-hit B-cell lymphomas.	MYD88
25347427	10.3109/10428194.2014.979413	2015	Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.	MYD88
25723115	10.1097/PAS.0000000000000411	2015	MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.	MYD88
25768255	10.1097/IAE.0000000000000589	2015	MyD-88 L265P mutations are present in some cases of vitreoretinal lymphoma.	MYD88
25816840	10.1111/bjh.13369	2015	Allele-specific PCR is a powerful tool for the detection of the MYD88 L265P mutation in diffuse large B cell lymphoma and decalcified bone marrow samples.	MYD88
25819228	10.1111/bjh.13361	2015	MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.	MYD88
25900979	10.1182/blood-2015-01-620518	2015	High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates.	MYD88
25978699	10.1089/gtmb.2015.0041	2015	MYD88 expression and L265P mutation in mature B-cell non-Hodgkin lymphomas.	MYD88
26099629	10.1111/bjd.13960	2015	Lack of myeloid differentiation primary response protein MyD88 L265P mutation in primary cutaneous marginal zone lymphoma.	MYD88
26159625	10.1016/j.jns.2015.06.026	2015	Bing-Neel syndrome: Two unexpected cases and a review of the literature.	MYD88
26230596	10.5858/arpa.2014-0322-OA	2015	Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.	MYD88
26388135	10.1111/pin.12336	2015	High prevalence of the MYD88 mutation in testicular lymphoma: Immunohistochemical and genetic analyses.	MYD88
24153350	10.1038/gene.2013.54	2014	Absence of somatic MYD88 L265P mutations in patients with primary Sjogren's syndrome.	MYD88
24253023	10.1038/leu.2013.348	2014	High prevalence of oncogenic MYD88 and CD79B mutations in primary testicular diffuse large B-cell lymphoma.	MYD88
24366360	10.1182/blood-2013-09-525808	2014	The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.	MYD88
24444466	10.1016/j.humpath.2013.10.023	2014	CD79B and MYD88 mutations in diffuse large B-cell lymphoma.	MYD88
24859878	10.3324/haematol.2014.108688	2014	Gamma heavy chain disease lacks the MYD88 L265p mutation associated with lymphoplasmacytic lymphoma.	MYD88
24903481	10.1038/leu.2014.184	2014	MYD88 (L265P) mutation is an independent prognostic factor for outcome in patients with diffuse large B-cell lymphoma.	MYD88
25055137	10.1001/jamadermatol.2014.821	2014	High frequency and clinical prognostic value of MYD88 L265P mutation in primary cutaneous diffuse large B-cell lymphoma, leg-type.	MYD88
25359991	10.1182/blood-2014-05-573188	2014	Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization.	MYD88
25501023	10.1038/bcj.2014.87	2014	Diffuse large B cell lymphomas relapsing in the CNS lack oncogenic MYD88 and CD79B mutations.	MYD88
22944768	10.1038/leu.2012.257	2013	IGHV gene features and MYD88 L265P mutation separate the three marginal zone lymphoma entities and Waldenström macroglobulinemia/lymphoplasmacytic lymphomas.	MYD88
23321251	10.1182/blood-2012-09-454355	2013	MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction.	MYD88
23355535	10.1182/blood-2012-09-457101	2013	Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms.	MYD88
23380077	10.1016/j.humpath.2012.10.026	2013	MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.	MYD88
23532735	10.1182/blood-2012-06-436329	2013	MYD88 L265P mutation in Waldenstrom macroglobulinemia.	MYD88
23666053	10.1007/s11033-013-2513-7	2013	Polymorphisms and haplotypes in MyD88 are associated with the development of sarcoidosis: a candidate-gene association study.	MYD88
23955458	10.1309/AJCP10ZCLFZGYZIP	2013	MYD88 L265P somatic mutation: its usefulness in the differential diagnosis of bone marrow involvement by B-cell lymphoproliferative disorders.	MYD88
24224040	10.1371/journal.pone.0080088	2013	L265P mutation of the MYD88 gene is frequent in Waldenström's macroglobulinemia and its absence in myeloma.	MYD88
22495176	10.1038/jid.2012.102	2012	MYD88 somatic mutation is a genetic feature of primary cutaneous diffuse large B-cell lymphoma, leg type.	MYD88
22640364	10.1111/j.1365-2141.2012.09176.x	2012	MYD88 somatic mutations in MALT lymphomas.	MYD88
22808296		2012	Mutation analysis of NF-κB signal pathway-related genes in ocular MALT lymphoma.	MYD88
22837180	10.1158/1078-0432.CCR-12-0845	2012	Recurrent mutations of MYD88 and TBL1XR1 in primary central nervous system lymphomas.	MYD88
22931316	10.1056/NEJMoa1200710	2012	MYD88 L265P somatic mutation in Waldenström's macroglobulinemia.	MYD88
21179087	10.1038/nature09671	2011	Oncogenically active MYD88 mutations in human lymphoma.	MYD88
22020631	10.1007/s00401-011-0891-2	2011	Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.	MYD88
20438785	10.1016/j.humimm.2010.04.004	2010	Polymorphisms in innate immunity genes and risk of childhood leukemia.	MYD88
19745833	10.1038/jhg.2009.90	2009	Polymorphisms and haplotypes in TLR9 and MYD88 are associated with the development of Hodgkin's lymphoma: a candidate-gene association study.	MYD88
